Abetimus

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Abetimus
Accession Number
DB06662
Type
Biotech
Groups
Investigational
Biologic Classification
Nucleic Acid Based Therapies
Oligonucleotides
Description

Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.

Synonyms
  • Abetimus
Product Ingredients
IngredientUNIICASInChI Key
Abetimus sodiumF5Y7739G6U169147-32-4Not applicable
International/Other Brands
Riquent
Categories
UNII
P3UVQ22SHK
CAS number
167362-48-3

Pharmacology

Indication

Investigated for use/treatment in kidney disease and systemic lupus erythematosus.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Abetimus.
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of adverse effects can be increased when Abetimus is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Abetimus.
ActeosideThe risk or severity of adverse effects can be increased when Abetimus is combined with Acteoside.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Abetimus.
Adenovirus type 7 vaccine liveThe risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Abetimus.
Adenovirus type 7 vaccine liveThe therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Abetimus.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Abetimus.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Abetimus.
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Abetimus.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Evidence Level

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Authors unspecified: Abetimus: Abetimus sodium, LJP 394. BioDrugs. 2003;17(3):212-5. [PubMed:12749759]
  2. Wallace DJ: Clinical and pharmacological experience with LJP-394. Expert Opin Investig Drugs. 2001 Jan;10(1):111-7. [PubMed:11116284]
External Links
Wikipedia
Abetimus
ATC Codes
L04AA22 — Abetimus

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2WithdrawnDiagnosticSystemic Lupus Erythematosus (SLE)1
3CompletedTreatmentAutoimmune Diseases / Immunologic Diseases / Lupus Glomerulonephritis / Nephritis, Lupus / Systemic Lupus Erythematosus (SLE)1
3TerminatedTreatmentNephritis, Lupus / Systemic Lupus Erythematosus (SLE)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on March 19, 2008 10:46 / Updated on May 18, 2019 18:11